Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001837935 | SCV002098181 | likely pathogenic | not provided | 2022-02-15 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 28961165) |
Labcorp Genetics |
RCV000497123 | SCV004539026 | uncertain significance | Neurofibromatosis, type 1 | 2023-11-10 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 354 of the NF1 protein (p.Lys354Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of neurofibromatosis type I (NF1) (PMID: 28961165). ClinVar contains an entry for this variant (Variation ID: 431576). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Medical Genetics, |
RCV000497123 | SCV000588710 | uncertain significance | Neurofibromatosis, type 1 | 2017-02-02 | no assertion criteria provided | clinical testing |